

Media Release

Zug, 28 September 2015

Advanced Accelerator Applications: Detailed Phase 3 Study Results Presented at the European Cancer Congress 2015 Demonstrate that Lutathera® Significantly Improves Progression-Free Survival in Patients with Advanced Midgut Neuroendocrine Tumors

- Four administrations of 7.4 GBq Lutathera® every eight weeks statistically significantly prolonged progression-free survival (PFS) in patients with advanced midgut neuroendocrine tumors ($p < 0.0001$; hazard ratio 0.21, 95% CI: 0.13-0.34).
- The median PFS in the Lutathera® arm is not yet reached whilst the median PFS in the Octreotide LAR 60mg arm was 8.4 months.
- Safety data generated from this study are consistent with the known safety profile of Lutathera®.

Advanced Accelerator Applications (“AAA”), the largest investment in the portfolio of privately held companies of HBM Healthcare Investments, presented yesterday detailed results showing that the pivotal Phase 3 NETTER-1 study for Lutathera® (^{177}Lu -DOTATATE) met its primary endpoint of assessing progression-free survival (PFS). The study demonstrated that Lutathera® significantly improved PFS when compared with Sandostatin® LAR® 60mg, in patients with advanced midgut neuroendocrine tumors (NETs).

The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera® was associated with a statistically significant and clinically meaningful risk reduction of 79% of disease progression or death versus a treatment with a double dose of Octreotide LAR (hazard ratio 0.21, 95% CI: 0.13-0.34; $p < 0.0001$). The median PFS in the Lutathera® arm is not yet reached, whilst the median PFS in the Octreotide LAR 60mg arm was 8.4 months. The adverse events observed on

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Lutathera® in the NETTER-1 study are consistent with the results of Lutathera®'s previous Phase I-II study, with Lutathera® demonstrating a favorable safety profile.

"NETTER-1 is the first large scale, multinational Phase 3 trial to demonstrate the efficacy of Lutathera® in patients with advanced midgut NETs," said Stefano Buono, Chief Executive Officer of AAA. *"We are very pleased with the favourable results demonstrated in the study. We believe that Lutathera® has the potential to provide a clinically significant benefit for patients and improve the standard of care for this disease."*

Dr. Andreas Wicki, CEO of HBM Healthcare Investments, commented: *"As a significant shareholder of AAA we are obviously very pleased with the outstanding study outcome. Our congratulations to Stefano and his team for achieving this milestone. The data set presented for Lutathera® confirms our view that AAA can become a very meaningful value contributor in our portfolio."*

Advanced Accelerator Applications is the largest investment in the portfolio of privately held companies of HBM Healthcare Investments. HBM invested the first time in early 2014 and increased its ownership further in 2015 to a total investment size of EUR 33.3 million. The investments is currently valued at EUR 38.8 million, based on the last round of financing. HBM is the largest shareholder of the company owning 9.45%.

Study Results in Detail

Enrolment was completed in February 2015, with a target of 230 patients randomized (1:1) in 36 sites in Europe and 15 sites in the United States. At the time of statistical analysis, the number of centrally confirmed disease progressions or deaths was 23 in the Lutathera® group and 67 in the Octreotide LAR 60mg group. The median PFS was not yet reached for Lutathera® and was 8.4 months with 60mg Octreotide LAR [95% CI: 5.8-11.0 months], $p < 0.0001$, with a hazard ratio of 0.21 [95% CI: 0.13-0.34]. Within the current evaluable patient dataset for tumor responses ($n=201$), 19 patients (19%) reported complete and partial responses (CR+PR) in the Lutathera® group versus 3 (3%) in the Octreotide LAR 60mg group ($p < 0.0004$). Although the overall survival (OS) data is not mature enough for a definitive analysis, the number of deaths was 13 in the Lutathera® group and 22 in the Octreotide LAR 60mg group ($p < 0.0186$ at interim analysis), which initially suggests an improvement in OS.

The Phase 3 NETTER-1 study provides evidence of a clinically meaningful and statistically significant increase in PFS and objective response rate (ORR), and also suggests a survival benefit in patients with advanced midgut neuroendocrine tumors treated with Lutathera®.

The adverse events observed on Lutathera® in the NETTER-1 study were generally consistent with their respective known adverse event profile.

HBM Healthcare Investments Ltd

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

All main secondary endpoints are currently being analyzed.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a radiopharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA's main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions ("Personalized Medicine"). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and currently has over 380 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S. and Canada). In 2014 AAA reported sales of €69.9 million (+29.9% vs. 2013). For more information please visit: www.adacap.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com